Zomedica 10Q 2024 Q3 Quarterly report

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024.

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________.

Commission File Number: 001-38298

Zomedica Corp.

(Exact name of registrant as specified in its charter)


Alberta, Canada		N/A
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)


100 Phoenix Drive, Suite 125 Ann Arbor, Michigan		48108
(Address of principal executive offices)		(Zip code)

(734) 369-2555

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	ZOM	NYSE American

As of November 7, 2024, 979,949,668 shares of the registrant’s common shares, without par value, were issued and outstanding.

Table of Contents

ZOMEDICA CORP.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

September 30, 2024

TABLE OF CONTENTS


		Page
PART I
FINANCIAL INFORMATION

Item 1.	Condensed Financial Statements	3
	Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023
	Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023
	Consolidated Statements of Shareholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023
	Notes to the Consolidated Financial Statements
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 4.	Controls and Procedures	36

PART II
OTHER INFORMATION
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 6.	Exhibits	38

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

Zomedica Corp.

Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023

(United States Dollars in Thousands)



	September 30,		December 31,
	2024		2023
Assets

Current assets
Cash and cash equivalents	$	9,747	$	12,952
Available-for-sale securities		67,128		77,545
Trade receivables, net		1,759		1,197
Inventory, net		5,429		5,123
Prepaid expenses and deposits		2,579		2,064
Other receivables		628		1,001
Total current assets		87,270		99,882

Prepaid expenses and deposits		196		250
Property and equipment, net		25,540		22,828
Right-of-use asset		1,828		2,466
Goodwill		45,556		61,580
Intangible assets, net		51,616		55,364
Non current available-for-sale securities		966		10,005
Other assets		1,143		822
Total assets	$	214,115	$	253,197

Liabilities and shareholders’ equity

Current liabilities
Accounts payable	$	2,376	$	2,068
Accrued income taxes		96		65
Current portion of lease obligations		632		916
Customer contract liabilities		293		276
Accrued expenses and other current liabilities		4,667		5,707
Total current liabilities		8,064		9,032

Lease obligations		1,445		1,814
Deferred tax liabilities		694		1,138
Customer contract liabilities		260		252
Other liabilities		808		944
Total liabilities	$	11,271	$	13,180

Commitments and contingencies (Note 15)

Shareholders’ equity
Unlimited common shares, no par value; 979,949,668 issued and outstanding at September 30, 2024 and December 31, 2023	$	380,973	$	380,973
Additional paid-in capital		32,292		29,929
Accumulated deficit		(210,721)		(170,933)
Accumulated comprehensive income		300		48
Total shareholders' equity		202,844		240,017

Total liabilities and shareholders’ equity	$	214,115	$	253,197

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Zomedica Corp.

Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023

(Unaudited) (United States Dollars in Thousands, Except for Per Share Data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net revenue	$	6,997	$	6,347	$	19,390	$	17,849
Cost of revenue		1,937		1,985		5,851		5,604
Gross profit		5,060		4,362		13,539		12,245

Expenses
General and administrative		6,765		6,115		23,366		19,977
Research and development		1,845		867		5,122		2,645
Selling and marketing		3,890		3,328		11,920		9,826
Impairment expense		—		—		16,024		—
Loss from operations		(7,440)		(5,948)		(42,893)		(20,203)
Interest income		977		1,437		3,108		4,309
Interest expense		—		(64)		—		(175)
(Loss) gain on disposal of assets		(134)		14		(173)		15
Other (loss) income, net		(111)		2,195		25		2,195
Foreign exchange loss		(16)		(45)		(191)		(54)
Loss before income taxes		(6,724)		(2,411)		(40,124)		(13,913)
Income tax benefit		(27)		(1,920)		(336)		(1,790)
Net loss		(6,697)		(491)		(39,788)		(12,123)
Unrealized gain, change in fair value of available-for-sale securities, net of tax		225		244		223		520
Change in foreign currency translation		139		(19)		29		(62)
Net loss and comprehensive loss	$	(6,333)	$	(266)	$	(39,536)	$	(11,665)

Weighted average number of common shares - basic and diluted		979,949,668		979,949,668		979,949,668		979,949,668

Loss per share - basic and diluted (Note 17)	$	(0.01)	$	(0.00)	$	(0.04)	$	(0.01)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Zomedica Corp.

Consolidated Statements of Shareholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023

(Unaudited) (United States Dollars in Thousands)


	Three Months Ended September 30, 2024
				Additional				Accumulated
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Income (Loss)		Total
Balance at June 30, 2024	979,949,668	$	380,973	$	31,832	$	(204,024)	$	(64)	$	208,717
Stock-based compensation	—		—		473		—		—		473
Stock issuance costs	—		—		(13)		—		—		(13)
Net loss	—		—		—		(6,697)		—		(6,697)
Other comprehensive income	—		—		—		—		364		364
Balance at September 30, 2024	979,949,668	$	380,973	$	32,292	$	(210,721)	$	300	$	202,844


	Nine Months Ended September 30, 2024
				Additional				Accumulated
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Income (Loss)		Total
Balance at December 31, 2023	979,949,668	$	380,973	$	29,929	$	(170,933)	$	48	$	240,017
Stock-based compensation	—		—		2,433		—		—		2,433
Stock issuance costs	—		—		(70)		—		—		(70)
Net loss	—		—		—		(39,788)		—		(39,788)
Other comprehensive income	—		—		—		—		252		252
Balance at September 30, 2024	979,949,668	$	380,973	$	32,292	$	(210,721)	$	300	$	202,844


	Three Months Ended September 30, 2023
				Additional				Accumulated
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Income (Loss)		Total
Balance at June 30, 2023	979,949,668	$	380,973	$	27,156	$	(148,035)	$	(612)	$	259,482
Stock-based compensation	—		—		1,668		—		—		1,668
Net loss	—		—		—		(491)		—		(491)
Other comprehensive income	—		—		—		—		225		225
Balance at September 30, 2023	979,949,668	$	380,973	$	28,824	$	(148,526)	$	(387)	$	260,884


	Nine Months Ended September 30, 2023
				Additional				Accumulated
	Common Stock			Paid-In		Accumulated		Comprehensive
	Shares	Amount		Capital		Deficit		Income (Loss)		Total
Balance at December 31, 2022	979,949,668	$	380,973	$	23,666	$	(136,403)	$	(845)	$	267,391
Stock-based compensation	—		—		5,158		—		—		5,158
Net loss	—		—		—		(12,123)		—		(12,123)
Other comprehensive income	—		—		—		—		458		458
Balance at September 30, 2023	979,949,668	$	380,973	$	28,824	$	(148,526)	$	(387)	$	260,884

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Zomedica Corp.

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023

(Unaudited) (United States Dollars in Thousands)


	Nine Months Ended September 30,
	2024		2023
Cash flows from operating activities:
Net loss	$	(39,788)	$	(12,123)
Adjustments for:
Depreciation		1,102		538
Amortization - intangible assets		4,834		3,890
Impairment loss		16,024		—
Loss (gain) on disposal of property and equipment		173		(15)
Gain on conversion of notes receivable		—		(2,174)
Stock-based compensation		2,433		5,158
Non cash portion of rent benefit		(15)		(2)
Accretion/amortization of available-for-sale securities		(1,608)		(1,716)
Equity in earnings of nonconsolidated entities		116		—
Deferred tax expense		(444)		(1,960)
Change in assets and liabilities, net of acquisitions:
Purchased inventory		(660)		(1,350)
Prepaid expenses and deposits		(460)		616
Trade receivables		(562)		(737)
Other receivables		570		193
Accounts payable		308		(547)
Accrued income tax		31		(73)
Deferred tax liabilities		—		—
Accrued expenses and other current liabilities		(1,048)		(524)
Customer contract liabilities		25		137
Other liabilities		(136)		(271)
Net cash used in operating activities		(19,105)		(10,960)

Cash flows from investing activities:
Securities matured		21,091		33,240
Investment in nonconsolidated entities		(437)		—
Investment in debt security (at fair value)		—		(1,750)
Investment in property and equipment		(4,637)		(9,304)
Acquisition of intangibles		(79)		(4,120)
Investment in acquisitions, net of cash acquired (SMP)		—		(12,660)
Net cash provided by investing activities		15,938		5,406

Cash flows from financing activities:
Stock issuance costs paid		(70)		—
Net cash used in financing activities		(70)		—

Decrease in cash and cash equivalents		(3,237)		(5,554)
Effect of exchange rate changes on cash		32		(62)
Cash and cash equivalents, beginning of year		12,952		27,399
Cash and cash equivalents, end of period	$	9,747	$	21,783

Noncash activities:
Change in fair value of available-for-sale securities, net of tax	$	223	$	520
Property and equipment accrued for in accounts payable		94		24
Transfer of property and equipment into intangibles		1,007		2,839
Transfer of inventory into property and equipment		354		582

Supplemental cash flow information:
Interest received on available-for-sale securities	$	1,755	$	2,550

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

1. Nature of Operations

Zomedica Corp. (“Zomedica” or the “Company”) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The Company consists of the parent company, Zomedica Corp., its wholly owned U.S subsidiary, Zomedica Inc., and the wholly owned subsidiaries of Zomedica Inc.

2. Basis of Preparation

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries. Intercompany transactions and balances between consolidated businesses have been eliminated. The accounting policies set out below have been applied consistently in the condensed consolidated financial statements.

The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Certain information and footnote disclosures normally included in financial statements have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary to present fairly the information required to be set forth therein. The Company’s management believes the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited consolidated financial statements and the notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on April 1, 2024 (“2023 Form 10-K”).

3. Significant Accounting Policies

Basis of Measurement

The condensed consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.

Business Combinations

We account for business combinations in accordance with ASC 805, Business Combinations (“ASC 805”), if the acquired assets assumed and liabilities incurred constitute a business. We consider acquired companies to constitute a business if the acquired net assets and processes have the ability to create outputs in the form of revenue. For acquired companies constituting a business, we recognize the identifiable assets acquired and liabilities assumed at their acquisition-date fair values and recognize any excess of total consideration paid over the fair value of the identifiable net assets as goodwill.

Estimates and Assumptions

In preparing these condensed consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Functional and Reporting Currencies

The functional currency for Canada and our subsidiaries in the United States and Switzerland is U.S. dollars, which is also our reporting currency. The functional currency, as determined by management, for our Japanese subsidiary is Japanese Yen. Japanese Yen is translated for financial reporting purposes, with translation gains and losses recorded as a component of other comprehensive income or loss. In respect of transactions denominated in currencies other than the Company’s and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

rates of exchange prevailing on the transaction dates. All exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations.

Comparative Figures

To better align with the way we track our business, we’ve combined construction in progress into property and equipment, net, for the nine months ended September 30, 2024. The consolidated balance sheets for the year ended December 31, 2023 have been adjusted to conform to the current year presentation of property and equipment, net. The change in presentation had no effect on the reported results in our balance sheets and does not affect previously reported cash flows from investing activities in the consolidated statements of cash flows.

To further enhance the transparency of our financial reporting, we have reclassified “Accounts payable” as its own line item, separating it from “Accounts payable and accrued liabilities.” Furthermore, we combined the accrued liabilities portion of “Accounts payable and accrued liabilities” with amounts previously included in “Other current liabilities” into a new line item, “Accrued expenses and other current liabilities”, to provide a comprehensive view of these obligations as of September 30, 2024. This presentation is supported by Note 10, “Accrued Expenses and Other Current Liabilities”, in the Notes to the Condensed Consolidated Financial Statements. The consolidated balance sheets for the year ended December 31, 2023, have been adjusted to align with the current presentation. The change in presentation had no impact on the reported results in our balance sheets and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows. Refer to Note 10 for further details.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The key amendments include: (a) introducing a new requirement to disclose significant segment expenses regularly provided to the chief operating decision maker (“CODM”), (b) extending certain annual disclosures to interim periods, (c) clarifying that single reportable segment entities must apply ASC 280 in its entirety, (d) permitting more than one measure of segment profit or loss to be reported under certain conditions, and (e) requiring disclosure of the title and position of the CODM. This ASU is effective for public entities with fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is in the process of reviewing the impact of this ASU and has not yet determined the impact of the adoption of this ASU on its consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public entities with fiscal years beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is in the process of reviewing the impact of this ASU and has not yet determined the impact of the adoption of this ASU on its consolidated financial statements.

Segment Reporting

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company’s reportable segments consist of Diagnostics and Therapeutic Devices.

Cash and Cash Equivalents

The Company considers all highly liquid securities with an original maturity of three months or less to be cash equivalents. As of September 30, 2024 and December 31, 2023, the Company's cash balances exceeded federally insured limits by approximately $1,468 and $1,308.

Investment Securities

Our investment securities, which are comprised of corporate bonds/notes and US treasuries, are accounted for in accordance with ASC 320, Investments – Debt Securities (“ASC 320”). The Company considers all of its securities for which there is a determinable fair

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

market value, and there are no restrictions on the Company’s ability to sell within the next twelve months, as available for sale. We classify these securities as both current and non-current depending on their time to maturity. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a component of comprehensive loss.

Accounts Receivable and Allowance for Credit Losses

Accounts receivables are recorded net of an allowance for credit losses and have payment terms of 30 days. Our policy for determining the allowance is based on factors that affect collectability, including: (a) historical trends of write-offs, recoveries, and credit losses; (b) the credit quality of our customers; and (c) projected economic and market conditions. As of September 30, 2024 and December 31, 2023, our allowances were $165 and $103, respectively, and were recorded net in trade receivables. While we believe that our allowance for credit losses is adequate and represents our best estimate as of September 30, 2024, we continue to closely monitor customer liquidity and industry and economic conditions, which may result in changes to these estimates.

Inventories

Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out ("FIFO") method to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

Property and Equipment

Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Property and equipment acquired in a business combination are recorded at fair value as of the date of acquisition. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss.

Included in property and equipment is construction in progress (“CIP”), which consists of property and equipment that are purchased or constructed and require time before being ready for their intended use. CIP is recorded at acquisition cost, including directly attributable installation costs. No depreciation is recorded on CIP until assets are complete and ready for use, at which point CIP balances are transferred to the appropriate property and equipment accounts, and depreciation begins in accordance with our policy.

Intangible Assets

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life.

Costs related to acquired customer relationships, developed technology, licenses, trademarks, and tradenames are capitalized and amortized over the estimated useful life. Intangible assets with finite useful lives that are acquired separately are carried at cost, less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the sum of estimated undiscounted future cash flows associated with the asset or group of assets is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

Revenue Recognition

The Company enters into agreements which may contain multiple promises where customers purchase products, services, or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services.

The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and extended warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The extended warranties are also a separate performance obligation, whereby revenue is recognized over time.

The Company also enters into contracts with customers where it receives payment for the consumable products and does not receive additional or separate consideration for the use of the point of care instrument furnished by the Company for the clinical veterinarian’s use. For these contracts, the Company considers the guidance under ASC 842, Leases (“ASC 842”), in order to determine if the furnishing of the point of care instrument to the customer during the period of use creates an embedded lease. If the point of care instrument is identified as a lease, it is classified as an operating lease as it does not meet any of the finance lease criteria per ASC 842. In these arrangements, the consumable products are classified as non-lease components. The Company allocates revenue to these lease and non-lease components based on standalone selling prices or, if not available, a cost-plus approach. Revenue related to the lease component is recognized ratably over the term of the contract. Revenue related to the non-lease components is recognized when control of the product has been transferred to the customer.

The nature of the Company’s PulseVet^® business gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned.

Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are nonrefundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode on hand with ample capacity to perform treatments.

At times, the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority.

Disaggregated revenue for the three and nine months ended September 30, 2024 and 2023 is as follows:


		Three Months Ended September 30,
		Diagnostics				Therapeutic Devices				Consolidated
		2024		2023		2024		2023		2024		2023
Capital	$	168	$	177	$	2,073	$	1,673	$	2,241	$	1,850
Consumables		339		190		4,370		4,292		4,709		4,482
Other		-		-		47		15		47		15
Total revenue	$	507	$	367	$	6,490	$	5,980	$	6,997	$	6,347

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)


		Nine Months Ended September 30,
		Diagnostics				Therapeutic Devices				Consolidated
		2024		2023		2024		2023		2024		2023
Capital	$	743	$	461	$	5,452	$	5,058	$	6,195	$	5,519
Consumables		927		555		12,153		11,710		13,080		12,265
Other		-		-		115		65		115		65
Total revenue	$	1,670	$	1,016	$	17,720	$	16,833	$	19,390	$	17,849

Cost of Revenue

Cost of goods sold consists of overhead, materials, labor, shipping costs, and a portion of depreciation incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of revenue.

Research and Development

Research and development costs related to continued research and development programs are expensed as incurred.

Stock-based Compensation

The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company’s stock-based compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest.

The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), on a tax jurisdictional basis. The Company files income tax returns in Canada and the province of Alberta and its subsidiaries file income tax returns in Switzerland, Japan, the United States and various states within, including in Michigan where the Company’s headquarters are located. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax basis of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.

The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in the United States, Canada, Japan, and Switzerland. The Company recognizes tax-related interest and penalties, if any, as a component separate from income tax expense.

Comprehensive Loss

Our comprehensive loss is reported in accordance with ASC 220, Income Statement — Reporting Comprehensive Income (“ASC 220”). Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity. The Company has recorded a currency translation adjustment associated with the translation of its Japanese subsidiary to the reporting currency.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

Loss Per Share

Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

4. Critical Accounting Judgments and Key Sources of Estimation Uncertainty

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and further periods if the revision affects both current and future periods.

Critical areas of estimation and judgements in applying accounting policies include the following:

Intangible Assets and Business Combinations

Assets acquired and liabilities assumed as part of a business combination are recognized at their acquisition date fair values. In determining these fair values, we utilize various forms of the income, cost, and market approaches depending on the asset or liability being valued.

We use a discounted cash flow model to measure the customer relationship, developed technology, license, trademark, and tradename assets. The estimation of fair value requires significant judgment related to future net cash flows based on assumptions related to revenue and EBITDA growth rates, discount rates, and attrition factors. Inputs are generally determined by taking into account competitive trends, market comparisons, independent appraisals, and historical data, among other factors, and are supplemented by current and anticipated market conditions.

Impairment Testing

We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change indicating the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic, industry and market factors; cost factors; changes in overall financial performance; and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we perform a test measuring the fair values of the reporting units and comparing them to their aggregate carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill.

We estimate the fair values of our reporting units using a discounted cash flow method or a weighted combination of discounted cash flows and a market-based method. The discounted cash flow method includes assumptions about a wide variety of internal and external factors. Significant assumptions used in the discounted cash flow method include financial projections of free cash flow, including revenue trends, medical costs trends, operating productivity, income taxes and capital levels; long-term growth rates for determining terminal value beyond the discretely forecasted periods; and discount rates. Financial projections and long-term growth rates used for our reporting units will be consistent with, and use inputs from, our internal long-term business plan and strategies.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty.

The passage of time and the availability of additional information regarding areas of uncertainty with respect to the reporting units’ operations could cause these assumptions to change in the future. Additionally, as part of our quantitative impairment testing, we perform various sensitivity analyses on certain key assumptions, such as discount rates, cash flow projections, and peer company multiples to analyze the potential for a material impact. The market-based method requires determination of an appropriate peer group whose securities are traded on an active market. The peer group is used to derive market multiples to estimate fair value.

Valuation and Payback of Property and Equipment

Diagnostic based TRUFORMA^® capital is placed in fixed assets once purchased or manufactured, where they remain, undepreciated, until they are placed with our customers under the agreement that they will repeatedly purchase consumables or services which are utilized within. Each instance of this placed capital represents an asset that we own. An estimate is made of the anticipated future revenue over its respective life which is ten years. If the payback period of the initial investment in the asset is less than the ten-year life of the asset, we conclude that the assets have been properly recorded, and no write-down is necessary. We rely on third-party data that considers various data points and assumptions, including, but not limited to, the expected volume of consumables which will be sold, anticipated growth rates, and anticipated placements. Realization of the anticipated revenue is dependent on the current assumptions and forecasted models.

Revenue Recognition and Liabilities Due to Customers

The nature of the Company’s business gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are estimated based upon historical experience and known trends. These estimated credits are non-refundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode at hand with ample capacity to perform treatments.

5. Investment Securities

The following represents the Company’s investment securities as of September 30, 2024 and December 31, 2023:


Balance at September 30, 2024		Acquisition Cost		Accretion / (Amortization)		Unrealized Gain / (Loss)		Estimated Fair Value
Commercial paper	$	14,456	$	459	$	15	$	14,930
Corporate notes / bonds		46,437		426		83		46,946
Money market funds		5,741		—		—		5,741
U.S. govt. agencies		3,441		18		—		3,459
U.S. treasuries		2,708		51		—		2,759
Total investment securities	$	72,783	$	954	$	98	$	73,835


Balance at December 31, 2023		Acquisition Cost		Accretion / (Amortization)		Unrealized Gain / (Loss)		Estimated Fair Value
Commercial paper	$	15,681	$	285	$	20	$	15,986
Corporate notes / bonds		45,954		614		(75)		46,493
Money market funds		5,374		—		—		5,374
U.S. govt. agencies		18,076		122		(33)		18,165
U.S. treasuries		10,282		156		(36)		10,402
Total investment securities	$	95,367	$	1,177	$	(124)	$	96,420

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

Accretion / (amortization) refers to the discounts and premiums incurred on bonds and notes purchased and are included within Interest income on our consolidated statements of operations and comprehensive loss.

Accrued interest receivable, related to the above investment securities, as of September 30, 2024 and December 31, 2023 amounted to $500 and $586, respectively, and is included in Other receivables on our consolidated balance sheets. Contractual maturities of investment securities as of September 30, 2024 are as follows (in thousands):


		Acquisition Cost		Estimated Fair Value
Original maturities of 90 days or less	$	5,741	$	5,741
Original maturities of 91-365 days		66,077		67,128
Original maturities of 366+ days		965		966
Total investment securities	$	72,783	$	73,835

6. Fair Value Measurements

In accordance with FASB ASC 820, Fair Value Measurement (“ASC 820”), the Company measures its cash and cash equivalents and investments at fair value on a recurring basis. The Company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting.

ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

As a basis for considering such assumptions, ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1:

Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2:

Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3:

Unobservable data points for the assets or liability, and include situations where there is little, if any, market activity for the asset or liability. Valuations based on inputs that are unobservable and involve management judgement and the reporting entity’s own assumptions about market participants and pricing.

Cash and cash equivalents, accounts receivable, and accounts payable: The carrying amount of these assets approximate fair value due to the short maturity of these instruments. Cash and cash equivalents include marketable securities with an original maturity within 90 days.

Available-for-sale securities: The Company classifies marketable securities and other highly liquid investments, with a maturity of greater than three months and that can be readily purchased or sold using established markets, as available-for-sale. These investments are reported at fair value on the Company’s consolidated balance sheets and unrealized gains and losses are reported as a component of shareholders’ equity.

Earnout liability: The Company has reported the fair value of the earnout liability within “Other liabilities” on the consolidated balance sheet. See footnote 7 for additional details.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

In accordance with the fair value hierarchy described above, the following table shows the fair value of our investments as of September 30, 2024 and December 31, 2023:


Balance at September 30, 2024		Level 1		Level 2		Level 3		Estimated Fair Value
Commercial paper	$	—	$	14,930	$	—	$	14,930
Corporate notes / bonds		—		46,946		—		46,946
Money market funds		5,741		—		—		5,741
U.S. govt. agencies		3,459		—		—		3,459
U.S. treasuries		2,759		—		—		2,759
Total investment securities	$	11,959	$	61,876	$	—	$	73,835


Balance at December 31, 2023		Level 1		Level 2		Level 3		Estimated Fair Value
Commercial paper	$	—	$	15,986	$	—	$	15,986
Corporate notes / bonds		—		46,493		—		46,493
Money market funds		5,374		—		—		5,374
U.S. govt. agencies		18,165		—		—		18,165
U.S. treasuries		10,402		—		—		10,402
Total investment securities	$	33,941	$	62,479	$	—	$	96,420

The following tables shows our investments as of September 30, 2024 and December 31, 2023 and their respective balance sheet classifications:


Balance at September 30, 2024		Cash & Cash Equivalents		Available- For-Sale (Current)		Available- For-Sale (Non-Current)		Estimated Fair Value
Commercial paper	$	—	$	14,930	$	—	$	14,930
Corporate notes / bonds		—		46,946		—		46,946
Money market funds		5,741		—		—		5,741
U.S. govt. agencies		—		2,493		966		3,459
U.S. treasuries		—		2,759		—		2,759
Total investment securities	$	5,741	$	67,128	$	966	$	73,835


Balance at December 31, 2023		Cash & Cash Equivalents		Available- For-Sale (Current)		Available- For-Sale (Non-Current)		Estimated Fair Value
Commercial paper	$	—	$	15,986	$	—	$	15,986
Corporate notes / bonds		—		36,973		9,520		46,493
Money market funds		5,374		—		—		5,374
U.S. govt. agencies		—		17,680		485		18,165
U.S. treasuries		3,496		6,906		—		10,402
Total investment securities	$	8,870	$	77,545	$	10,005	$	96,420

Unrealized gains on our investments have not been recorded into income as we do not intend to sell nor is it more likely than not that we will be required to sell these investments prior to recovery of their amortized cost basis. The decline in fair value of our debt securities is largely due to the rising interest rate environment driven by current market conditions that have resulted in higher credit spreads. The credit ratings associated with our debt securities are mostly unchanged, are highly rated, and the debtors continue to make timely principal and interest payments. As a result, there were no credit or non-credit impairment charges recorded through September 30, 2024.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

7. Business Combinations

All of the Company’s acquisitions of businesses have been accounted for under ASC 805. Accordingly, the assets of the acquired companies reflect the fair values and have been included in the Company’s Condensed Consolidated Financial Statements from their respective dates of acquisition.

The results of operations of Revo Squared LLC, Assisi Animal Health, LLC, Structured Monitoring Products, Inc, and Qorvo Biotechnologies, LLC have been included in the Company’s Condensed Consolidated Financial Statements since the dates of acquisition on June 14, 2022, July 15, 2022, September 4, 2023, and October 4, 2023 respectively.

2022 Acquisitions

Asset Purchase Agreement with Revo Squared LLC

On June 14, 2022, Zomedica Corp. and its wholly owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement with Revo Squared LLC (“Revo Squared”) and its majority member pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets of Revo Squared. Revo Squared, based in Marietta, Georgia, was in the business of developing, manufacturing, marketing, distributing, and selling diagnostic imaging products and services for use in animal health, including its SuperView™, Sonoview^® Color ultrasound, Sonoview Mini/Mini Plus ultrasound, and Microview^® product offerings.

On July 1, 2022, the parties consummated the acquisition. At the closing, Zomedica Inc. paid Revo Squared a base purchase price of $6,011 in cash, which was subject to adjustments based on the amount of Revo Squared’s working capital at the closing. On this date, $500 of the purchase price was deposited into a third-party escrow account for a period of fifteen months to support Revo Squared’s indemnification obligation under the Purchase Agreement. No indemnification claims were made during this period resulting in the $500 being released from the escrow to the seller. The Company also issued to Revo Squared a ten-year warrant to purchase an aggregate of 10,000,000 of the Company’s common shares at a per share exercise price equal to $0.2201. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder.

In addition, Zomedica Inc. has agreed to pay Revo Squared aggregate earn-out payments ranging from $0 to $4,000 based on the achievement of milestones related to future net sales from Revo Squared Products. One-time earn-out payments of $2,000 each will be payable upon net sales from Revo Squared Products exceeding $5,000 and $10,000 during any calendar year ending on or prior to December 31, 2027. The fair value of the earnout liability was adjusted from $2,000 to $447 at September 30, 2024. Fair value of the earnout was determined using Level 3 inputs.

As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $6,528 was recorded in connection with this acquisition, which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base.

The Company finalized the allocation of the purchase price for Revo Squared as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:


	Initial		Measurement
	Allocation of		Period		Updated
	Consideration		Adjustments		Allocation
Trade receivables, net	$	8	$	—	$	8
Prepaid expenses and deposits		10		—		10
Intangible Assets (estimated useful life)
Trade name (5 years)		200		—		200
Developed technology (10 years)		2,300		—		2,300
Customer relationships (16 years)		1,200		—		1,200
Total assets acquired		3,718		—		3,718

Earnout liabilities		2,458		(458)		2,000
Total liabilities assumed		2,458		(458)		2,000

Net assets acquired, excluding goodwill		1,260		458		1,718
Goodwill		6,528		(458)		6,070

Net assets acquired	$	7,788	$	—	$	7,788

Purchase price consideration was made up of the following:


Cash	$	6,011
Fair value of warrants		1,777
Total	$	7,788

Asset Purchase Agreement with Assisi Animal Health LLC

On July 15, 2022, Zomedica Corp. and its wholly owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement with Assisi Animal Health LLC (“Assisi”), its wholly owned subsidiary, AAH Holdings LLC, and certain of Assisi’s members (collectively the “Seller”) pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets related to the Assisi® product lines. The Sellers were in the business of developing, manufacturing, marketing, distributing and selling animal health products which use targeted Pulsed Electromagnetic Field (PEMF) therapy to decrease pain and inflammation, accelerate healing, and reduce anxiety that include the Assisi Loop^®, Assisi Loop Lounge^®, Assisi DentaLoop^® and Calmer Canine™ product lines.

Zomedica Inc. paid Assisi a purchase price of $18,293 in cash, which was subject to adjustments based on, among other things, the value of Assisi’s inventory and prepaid expenses at the closing of the acquisition. A portion of the purchase price ($1,400) was deposited into a third-party escrow account. The balance of the escrow account was released to seller on the 18-month anniversary of the Closing Date as there were no indemnification claims. The Company also issued to Assisi a ten-year warrant to purchase an aggregate of 22,000,000 of the Company’s common shares at a per share exercise price equal to $0.252. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder.

As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $14,329 was recorded in connection with this acquisition, which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base.

The Company finalized the allocation of the purchase price for Assisi as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:


	Initial		Measurement
	Allocation of		Period		Updated
	Consideration		Adjustments		Allocation
Inventory, net	$	220	$	—	$	220
Prepaid expenses and deposits		271		—		271
Other receivables		406		(206)		200
Right of use asset		—		260		260
Intangible Assets (estimated useful life)
E-commerce technology (2 years)		200		—		200
Trade name (5 years)		300		—		300
Developed technology (10 years)		4,500		—		4,500
Customer relationships (19 years)		2,800		—		2,800
Total assets acquired		8,697		54		8,751

Current portion of lease obligations		—		49		49
Non current portion of lease obligations		—		211		211
Other non current liabilities		45		—		45
Total liabilities assumed		45		260		305

Net assets acquired, excluding goodwill		8,652		(206)		8,446
Goodwill		14,329		206		14,535

Net assets acquired	$	22,981	$	—	$	22,981

Purchase price consideration was made up of the following:


Cash	$	18,293
Fair value of warrants		4,688
Total	$	22,981

2023 Acquisitions

Stock Purchase Agreement with Structured Monitoring Products, Inc.

On September 4, 2023, Zomedica Inc., a wholly owned subsidiary of Zomedica Corp. (the “Company”), entered into a Stock Purchase Agreement with Structured Monitoring Products, Inc. pursuant to which Zomedica Inc. acquired 100% of the capital stock of Structured Monitoring Products, Inc., a Florida corporation (“SMP”). SMP is the maker of VetGuardian^®, a zero-touch vital signs remote monitoring system that improves the quality of care for pets during recovery from surgery and for those staying in clinic overnight. The system provides real-time remote monitoring of the pet’s vital signs with the ability to alert staff if the vital signs fall outside preset ranges (the “Acquisition”). The Acquisition was consummated on September 5, 2023.

In connection with the Acquisition, the Company converted $2,750 in convertible debt and accrued interest of $171 owed by SMP to the Company into equity totaling 28.7% outstanding equity of SMP, which has an implied value of $5,095 based upon the SMP’s enterprise value of $18,000. Zomedica paid a purchase price of $12,952 for the balance of 71.3% equity of SMP. The cash purchase price was funded through a $250 deposit previously paid to SMP and $12,702 of cash on hand. At closing, Zomedica deposited $1,295 in escrow. $215 was released at 90 days as there were no adjustments to the working capital, cash, indebtedness, and transaction expenses. The remaining balance will be released 18 months following the date of closing less the amount of any pending or prior indemnification claims.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $9,796 was recorded in connection with the Acquisition, none of which will be deductible for U.S tax purposes. The goodwill is mainly attributable to skills and technical talent of SMP’s work force and the synergies expected to be achieved from integrating SMP into the Company’s existing business.

The previously held equity interests were remeasured to its fair value as of the acquisition date. The Company computed the fair value based upon the SMP’s enterprise value of $18,000 and the fair value of previously held 28.7% equity interests were determined to be $5,095. The Company recognized an amount of $2,174 as a gain on the fair valuation of Company’s previously held equity interest in SMP and was included in other income (loss) in our 2023 Form 10-K as part of our consolidated statements of operations and comprehensive loss for the period ended December 31, 2023.

The following table summarizes the final fair value amounts of identifiable assets acquired and liabilities assumed at the acquisition date:



	Allocation of
	Consideration
Cash and cash equivalents	$	42
Trade receivables, net⁽¹⁾		11
Inventory, net		316
Other receivables		1
Intangible assets (estimated useful life)
Developed technology (10 years)		9,400
Non-competition agreement (3 years)		200
Total assets acquired		9,970

Accounts payable		6
Deferred tax liabilities		1,713
Total liabilities assumed		1,719

Net assets acquired, excluding goodwill		8,251
Goodwill		9,796

Net assets acquired	$	18,047

(1)	The “trade receivables, net” comprise gross contractual amounts due of $11, of which no amounts were expected to be uncollectable at the date of acquisition.

The Company evaluated the disclosure requirements under ASC 805 and determined SMP was not considered a material business combination for purposes of disclosing the earnings of SMP since the date of acquisition and supplemental pro forma information.

Purchase price consideration was made up of the following:


Cash	$	12,702
Fair value of previously held interest		5,095
Prepaid deposits		250
Net assets acquired	$	18,047

Cash	$	12,702
Less: cash acquired		(42)
Investment in acquisitions, net of cash acquired	$	12,660

LLC Membership Interest Purchase Agreement for the Acquisition of Qorvo Biotechnologies, LLC

On October 4, 2023, Zomedica Inc., a wholly owned subsidiary of Zomedica Corp. (the “Company”), entered into an LLC Membership Interest Purchase Agreement with Qorvo US, Inc. (“Qorvo”) pursuant to which Zomedica Inc. acquired 100% of the membership

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

interests of Qorvo Biotechnologies, LLC, a Delaware limited liability company (“QBT”) from Qorvo. QBT develops the TRUFORMA^® Platform that utilizes innovative Bulk Acoustic Wave sensor technology to provide a non-optical and fluorescence free system for the detection of disease at the point of care (the “Acquisition”). The Acquisition was consummated on October 4, 2023.

Zomedica paid Qorvo a purchase price of $7,646, which comprised of cash of $11,300 and settlement of pre-existing relationship of $3,654. The cash purchase price was funded through the cash on hand.

The following table summarizes the fair value amounts of identifiable assets acquired and liabilities assumed at the acquisition date:


	Initial		Measurement
	Allocation of		Period		Updated
	Consideration		Adjustments		Allocation
Inventory, net	$	1,674	$	(201)	$	1,473
Other receivables		52		—		52
Property and equipment, net		6,495		201		6,696
Right-of-use asset		1,202		—		1,202
Other assets		19		—		19
Total assets acquired		9,442		—		9,442

Accounts payable and accrued liabilities		594		—		594
Current portion of lease obligations		249		—		249
Lease obligations		953		—		953
Total liabilities assumed		1,796		—		1,796

Net assets acquired, excluding goodwill		7,646		—		7,646

Net assets acquired	$	7,646	$	—	$	7,646

The Company incurred $499 in acquisition costs that were expensed in the period incurred and are included in general and administrative expense in the accompanying consolidated statements of operations and comprehensive loss.

The Company evaluated the disclosure requirements under ASC 805 and determined QBT was not considered a material business combination for purposes of disclosing the earnings of QBT since the date of acquisition and supplemental pro forma information.

Purchase price consideration was made up of the following:


Cash	$	11,300
Settlement of pre-existing relationship⁽¹⁾		(3,654)
Total	$	7,646

(1)

The Company had entered into a Development and Manufacturing License Agreement with QBT on January 17, 2023 and the Company had an intangible asset and liability balance of $6,945 and $3,654, respectively as of the acquisition date related to this agreement. The effect of the pre-existing liability (i.e., $3,654) is included in the consideration transferred.

The determination of the final purchase price allocation to specific assets, primarily fixed assets, is incomplete and may change in future periods in the event that the intended uses of the assets change as we continue to deploy and integrate operations.

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

8. Inventory


	September 30, 2024						December 31, 2023
	Diagnostics		Therapeutic Devices		Consolidated		Diagnostics		Therapeutic Devices		Consolidated
Raw materials	$	2,046	$	2,628	$	4,674	$	1,801	$	2,026	$	3,827
Finished goods		34		250		284		141		256		397
Purchased inventory		200		278		478		331		617		948
Total		2,280		3,156		5,436		2,273		2,899		5,172

Less: reserves		(7)		—		(7)		(49)		—		(49)
Net inventory	$	2,273	$	3,156	$	5,429	$	2,224	$	2,899	$	5,123

9. Prepaid Expenses and Deposits


	September 30,		December 31,
	2024		2023
Deposits	$	244	$	919
Prepaid marketing		488		259
Prepaid insurance		610		436
Other		1,433		700
Total prepaid expenses and deposits	$	2,775	$	2,314

10. Accrued Expenses and Other Current Liabilities


	September 30,		December 31,
	2024		2023
Accrued employee compensation and benefits	$	2,834	$	4,131
Accrued taxes		949		1,069
Accrued professional services		642		145
Other		242		362
Total accrued expenses and other current liabilties	$	4,667	$	5,707

11. Property and Equipment


	September 30,		December 31,
	2024		2023
Machinery and office equipment	$	10,083	$	9,142
Furniture and equipment		223		224
Laboratory equipment		857		1,073
Leasehold improvements		3,083		1,953
Construction in progress		14,298		12,481
		28,544		24,873

Less: accumulated depreciation and amortization		(3,004)		(2,045)
Net property and equipment	$	25,540	$	22,828

Depreciation expense related to property and equipment is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Depreciation expense	$	417	$	198	$	1,102	$	538

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

During the nine months ended September 30, 2024, in line with ASC 360, Property, Plant, and Equipment (“ASC 360”), the Company conducted a review of its property and equipment for recoverability. This assessment was prompted by broader reviews within our reporting units. It was concluded that the carrying values of our plant and equipment assets were fully recoverable, resulting in no impairment charge being recognized as of September 30, 2024.

12. Goodwill and Intangible Assets

The following table provides a rollforward of the carrying amount of goodwill by segment:


	Diagnostics		Therapeutic Devices		Total
Goodwill - December 31, 2023	$	15,866	$	45,714	$	61,580

Acquisitions		—		—		—
Adjustment to Purchase Price Allocations		—		—		—
Impairment		(15,866)		(158)		(16,024)

Goodwill - September 30, 2024	$	(0)	$	45,556	$	45,556

During the nine months ended September 30, 2024, the Company concluded it was more likely than not that the fair values of certain of its reporting units had declined below their carrying values due to slowed sales growth projections and the allocation of operating expenses. The Company completed an interim goodwill impairment analysis in accordance with ASC 350, Intangibles – Goodwill and Other (“ASC 350”). The difference between the reporting units’ carrying values and fair values was recognized as impairment charges.

The Company recognized $0 and $16,024 in non-cash impairment charges related to its goodwill during the three and nine months ended September 30, 2024. This amount represented the full impairment of the goodwill in two reporting units in the Diagnostics segment and the partial impairment of goodwill in one reporting unit in the Therapeutic Devices segment. This charge is recorded under “Impairment expense” in our consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2024.

As part of our interim impairment analysis during the nine months ended September 30, 2024, the Company also evaluated its amortizable intangible assets for recoverability under ASC 360. The results of the assessment confirmed that the fair values of these assets continued to exceed their carrying amounts. As a result, no impairment charges were recognized.

The following table summarizes our intangible assets, net of accumulated amortization:


	September 30,		December 31,
	2024		2023
Computer software	$	2,827	$	1,741
Customer relationships		26,850		26,850
Licenses		8,042		8,042
Technology		25,050		25,050
Trademarks		16		16
Tradename		2,850		2,850
Website		962		962
		66,597		65,511

Less: accumulated amortization		(14,981)		(10,147)
Net intangibles	$	51,616	$	55,364

Included within intangibles are $563 in licenses associated with future exclusivity to sell products should we determine that they have both market viability and are a complementary fit within our suite of offerings. As these relationships are still in the exploratory phase with no revenue stream to match expenses against nor a guarantee that this exclusivity will ever be used, we are considering these to be indefinite lived as of September 30, 2024. This accounts for the difference between the net intangibles as found within our consolidated

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

balance sheets and the amortization table below. We will continue to assess the commercialization status and relationship with these companies on a quarterly basis and will adjust our amortization schedules accordingly.

The estimated future amortization of intangible assets is as follows:


2024	$	1,605
2025		6,319
2026		5,854
2027		5,627
2028		5,577
2029 and thereafter		26,071
Total	$	51,053

Amortization expense associated with intangible assets is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Amortization expense	$	1,611	$	1,398	$	4,834	$	3,890

13. Stock-Based Compensation

The Zomedica Amended and Restated Stock Option Plan ( the “Plan”) was amended and restated on June 15, 2022, and provides incentives through the grant of stock options which may be granted to the directors, officers, and employees of the Company. The Plan is administered by the board of directors of the Company, and the aggregate number of shares reserved for issuance under the Plan shall not, at the time of the stock option grant, exceed ten percent of the total number of issued and outstanding shares (calculated on a non-diluted basis). If any stock options granted under this Plan shall expire or terminate for any reason without having been exercised in full, they shall be available for the purposes of granting new stock options under this Plan.

During the nine months ended September 30, 2024 and 2023, the Company issued 4,325,000 and 9,275,000 stock options to purchase an aggregate of 4,325,000 and 9,275,000 common shares, respectively. These options vest over a period of four years and have an expiration period of 10 years.

The continuity of stock options for the nine months ended September 30, 2024 and 2023 are as follows:


	Number of	Weighted Avg
	Options	Exercise Price
Balance at December 31, 2023	93,349,943	$	0.3338
Stock options granted	4,325,000		0.1450
Stock options forfeited	9,457,500		0.2102
Vested stock options expired	1,355,500		0.4861
Balance at September 30, 2024	86,861,943	$	0.3355
Vested at September 30, 2024	47,347,774	$	0.3520


	Number of	Weighted Avg
	Options	Exercise Price
Balance at December 31, 2022	84,112,443	$	0.3602
Stock options granted	9,275,000		0.2327
Stock options forfeited	2,507,500		0.3292
Vested stock options expired	1,002,500		0.9126
Balance at September 30, 2023	89,877,443	$	0.3397
Vested at September 30, 2023	31,648,974	$	0.3476

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

The Company recorded the following stock-based compensation expense:


	Three Months Ended September 30,				Nine Months Ended September 30,
		2024		2023		2024		2023
Stock-based compensation expense	$	473	$	1,668	$	2,433	$	5,158

As of September 30, 2024, the total unrecognized compensation cost related to nonvested awards was $2,727, which is expected to be recognized over a weighted-average period of 2.0 years.

14. Income Taxes

The Company is in an overall domestic net deferred tax liability position for the nine months ended September 30, 2024. Management has assessed that the future taxable income resulting from the deferred tax liability position will result in partial utilization of the Company's US federal and state net operating loss carryforwards and has therefore concluded a valuation allowance of $15,302 is currently necessary. Due to the uncertainty of realizing any tax benefits as of September 30, 2024 due to historical losses, a full valuation allowance remains necessary to fully offset our Canadian deferred tax assets.

15. Commitments and Contingencies

From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As of September 30, 2024, and continuing as of November 7, 2024, the Company is not aware of any pending or threatened material litigation claims against the Company.

On May 10, 2018, the Company entered into a Development, Commercialization and Exclusive Distribution Agreement. As part of the agreement, the Company is required to make the following future milestone payments:

●

$3,500 in cash payments upon the achievement of future development milestones;

●

$3,500 in equity, determined by dividing the amount due by the volume-weighted average price of the Company’s common stock on the NYSE American exchange over the 10 trading days prior to the achievement of each milestone event.

As of September 30, 2024, none of the future development milestones related to the above agreement have been met. The Company has assessed the probability of meeting the above milestones and has determined that an accrual is not necessary as of September 30, 2024 and December 31, 2023.

On January 17, 2023, the Company entered into a series of agreements with Qorvo Biotechnologies, LLC. Other than the obligation to purchase a minimum quantity of BAW sensors during the term of the BAW Sensor Supply Agreement, the obligations under these agreements were terminated upon the acquisition of Qorvo Biotechnologies, LLC on October 4, 2023.

On April 4, 2023, the Company entered into a Development and License Agreement with Brisby Inc. Under the terms of this agreement, Brisby grants the Company a license to use, develop, manufacture, have manufactured, offer for sale, sell, and import certain Brisby products, such as the Smart Pet Pad and the Intelligent Pet Bed, along with any future developments of these products.

As part of this agreement, the Company is required to make the following milestone payments:

●

$3,500 in cash payments, split between license fees and equity interest, upon the achievement of future development milestones, inclusive of development milestones and commercial sales;

●

$750 in warrants upon the first commercial sale of the Smart Pet Pad, determined by dividing the amount due by the closing price of the Company's common stock on the date of such first commercial sale, as reported on the NYSE American exchange, with a term of 10 years;

●

$750 in warrants upon the first commercial sale of the Intelligent Pet Bed, determined by dividing the amount due by the closing price of the Company's common stock on the date of such first commercial sale, as reported on the NYSE American exchange, with a term of 10 years;

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

●

$5,000 in warrants upon reaching $15,000 in annual net sales of the licensed products, determined by dividing the amount due by the closing price of the Company's common stock on the date that net sales reach $15,000, as reported on the NYSE American exchange.

As of September 30, 2024, the Company has made $1,563 in cash payments for milestones achieved under this agreement and holds a 19.50% equity stake in Brisby Inc. The remaining cash payments, totaling $1,937, are due upon the achievement of future development milestones and the first commercial sales of the Smart Pet Pad and the Intelligent Pet Bed.

The Company’s investment in Brisby Inc. is accounted for under the equity method in accordance with ASC 323, Investments – Equity Method and Joint Ventures (“ASC 323”), and is included in “Other assets” on our consolidated balance sheets.

16. Segment Information

The Company’s operations are comprised of two reportable segments:

●

Diagnostics, which consists of TRUFORMA®, VetGuardian®, and TRUVIEW™ products; and

●

Therapeutic Devices, which consists of Assisi® and PulseVet® products. The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer who has ultimate responsibility for enterprise decisions.

Although our reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution / development partners. The CODM determines resource allocation for, and monitors performance of, the consolidated enterprise, the Diagnostics segment, and the Therapeutic Devices segment together. The CODM relies on internal segment reporting that analyzes results on certain key performance indicators, namely, revenues and gross profit. Costs below gross profit are not allocated to the segments nor are asset groupings except for the purpose of periodic impairment analysis.

The following is a reconciliation of consolidated revenue, cost of revenue, and gross profit amongst our reportable segments for the three and nine months ended September 30, 2024 and 2023:


	Three Months Ended September 30,
	Diagnostics				Therapeutic Devices				Consolidated
	2024		2023		2024		2023		2024		2023
Net revenue	$	507	$	367	$	6,490	$	5,980	$	6,997	$	6,347
Cost of revenue		396		476		1,541		1,509		1,937		1,985
Gross (loss) profit	$	111	$	(109)	$	4,949	$	4,471	$	5,060	$	4,362


	Nine Months Ended September 30,
	Diagnostics				Therapeutic Devices				Consolidated
	2024		2023		2024		2023		2024		2023
Net revenue	$	1,670	$	1,016	$	17,720	$	16,833	$	19,390	$	17,849
Cost of revenue		1,441		1,220		4,410		4,384		5,851		5,604
Gross (loss) profit	$	229	$	(204)	$	13,310	$	12,449	$	13,539	$	12,245

Table of Contents

Zomedica Corp.
Notes to the Condensed Consolidated Financial Statements
(United States Dollars in Thousands)

17. Loss Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Numerator
Net loss for the period	$	(6,697)	$	(491)	$	(39,788)	$	(12,123)

Denominator
Weighted average shares - basic		979,949,668		979,949,668		979,949,668		979,949,668

Loss per share - basic and diluted	$	(0.01)	$	(0.00)	$	(0.04)	$	(0.01)

As of September 30, 2024, and 2023, the Company had stock options outstanding of 86,861,943 and 89,877,443, respectively, and warrants outstanding of 32,561,418 for both periods. These securities could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would be anti-dilutive.

18. Subsequent Events

We have evaluated events and transactions occurring subsequent to the consolidated balance sheet date of September 30, 2024 for items that could potentially be recognized or disclosed in these financial statements. We did not identify any items which would require disclosure in or adjustment to the consolidated financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATION

(All amounts are expressed in thousands unless otherwise indicated)

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help the reader understand the results of operations and financial condition of the Company. The Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and notes thereto for the quarter ended September 30, 2024. This report contains forward-looking statements or forward-looking information (collectively, “forward-looking statements”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as the safe harbor provisions of applicable Canadian securities legislation, that are based on management’s beliefs and assumptions and involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.

Forward-looking statements can also be identified by words such as “future”, “anticipates”, “believes”, “projects”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “will”, “should”, “would”, “could”, “can”, “may”, or similar terms. Forward-looking statements are not guarantees of future performance and Zomedica’s actual results may differ significantly from the results discussed in the forward-looking statements. Zomedica cautions that these statements are subject to numerous important risks, uncertainties, assumptions, and other factors, some of which are beyond Zomedica’s control. These risks could cause Zomedica’s actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, risks related to adverse macroeconomic conditions; changes in consumer confidence and spending in response to economic volatility; our ability to develop and commercialize our products; our ability to integrate our acquisitions successfully into our business; supply chain disruptions that increase our costs and impair our ability to manufacture our products; our ability to attract and keep senior management and key scientific personnel; our ability to obtain and maintain intellectual property protection; our ability to maintain the listing of our common shares on the NYSE American exchange; the accuracy of our estimates regarding expenses, future revenues, and capital requirements; and the “Risk Factors” described in our Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”). The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We undertake no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, except as required by applicable law.

Components of Revenue and Costs and Expenses

Revenue

Our revenue consisted of consumables sold in the U.S. and internationally associated with our Assisi^® products; capital and consumables sold in the U.S and internationally associated with our PulseVet^® platform; consumables sold in the U.S associated with our TRUFORMA^® platform; subscriptions and services sold in the U.S. associated with our TRUVIEW™ products; and capital and service agreements sold in the U.S. and internationally associated with our VetGuardian^® products.

Cost of Revenue

Cost of revenue consisted primarily of the cost of raw materials used in the assembly of: PulseVet^® capital and consumables; TRUFORMA^® capital and consumables; Assisi consumables; TRUVIEW™ capital and consumables; and VetGuardian^® capital and services. We expense all inventory obsolescence provisions related to normal manufacturing changes as cost of revenue.

Table of Contents

Operating Expenses

Our current operating expenses consist of three components — general and administrative expenses, research and development expenses, and selling and marketing expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, wages, stock-based compensation, and overhead costs incurred to support our business as a publicly traded company. The functions involved include Accounting, Business Development, Finance, HR, Information Technology, Investor Relations, Legal, and portions of other functional areas. Included within these support costs are significant public company expenses such as stock exchange fees, annual meeting expenses, and audit, tax, Sarbanes-Oxley, and other compliance costs.

Research and Development Expenses

Research and development expenses consist of salaries and related expenses for R&D personnel, fees paid to consultants and outside service providers, travel costs, and materials used in clinical trials and general research and development. These costs are primarily focused on leveraging our recent acquisition of Qorvo into new assay development for our TRUFORMA^® platform, expanding capabilities and usability within existing products, and exploring new market opportunities.

Selling and Marketing Expenses

Selling and marketing expenses consist of personnel costs (including salaries and related benefits) and costs associated with sales and marketing activities (including conference and tradeshow attendance, sponsorships, and general advertising and promotional activities).

Inflation Reduction Act

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023.

The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax, such as repurchases under $1 million.

Any redemption or other repurchase that occurs after December 31, 2023, in connection with a business combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent we would be subject to the excise tax in connection with a business combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the business combination, extension or otherwise; (ii) the structure of a business combination; (iii) the nature and amount of any equity issuances in connection with a business combination (or otherwise issued not in connection with a business combination but issued within the same taxable year of a business combination); and (iv) the content of regulations and other guidance from the U.S. Department of the Treasury.

The IR Act also included a new 15% Corporate Alternative Minimum Tax (“CAMT”) that acts as a new book minimum tax of at least 15% of consolidated U.S. GAAP pre-tax income for corporations with average book income in excess of $1 billion. Any increase in our effective tax rate will depend on a number of factors, including any offsets for general business credits or changes in book income following business combinations. The CAMT is effective for tax years beginning on or after January 1, 2023. Lastly, the IR Act also creates several potentially beneficial tax credits to incentivize investments in certain technologies and industries.

We are in the process of evaluating the potential impacts of the IR Act. While we do not believe the IR Act will have a material negative impact on our business or our financial performance, the effects of the measures are unknown at this time. Our analysis is ongoing and incomplete, and it is possible that the IR Act could ultimately have a material adverse effect on our tax liability. We continue to monitor the IR Act and related regulatory developments to evaluate their potential impact on our business, tax rate and financial results.

Table of Contents

Canadian Taxes

In Canada, due to the uncertainty of realizing any tax benefits as of September 30, 2024, we continue to record a full valuation allowance against our Canadian deferred tax assets.

Translation of Foreign Currencies

The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is the U.S. dollar, which is also our reporting currency.

The functional currency, as determined by management, for our Japanese subsidiary is the Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss.

Stock-Based Compensation

We measure the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.

We calculate stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of our stock-based compensation plans do not require us to settle any options by transferring cash or other assets, and therefore we classify the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. We estimate forfeitures at the time of grant and revise these estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options. The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is zero as we are not expected to pay dividends in the foreseeable future.

Loss Per Share

Basic loss per share, or EPS (earnings per share), is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.

Comprehensive Loss

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue, costs and expenses, and related disclosures during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

While our significant accounting policies are more fully described in Note 3 of the notes to our consolidated financial statements included within our 2023 Form 10-K, management has identified the following as “Critical Accounting Policies and Estimates”: Intangible Assets and Business Combinations; Impairment Testing; Valuation and Payback of Property and Equipment; and Revenue Recognition and Liabilities Due to Customers. We believe that the estimates and assumptions involved in these accounting policies may have the greatest potential impact on our financial statements.

Intangible Assets and Business Combinations

Assets acquired and liabilities assumed as part of a business combination are recognized at their acquisition date fair values. In determining fair values for recent business combinations, we utilize various forms of the income, cost, and market approaches depending on the asset or liability being valued.

We use a discounted cash flow model to measure the customer relationship, developed technology, license, trademark, and tradename assets. The estimation of fair value requires significant judgment related to future net cash flows based on assumptions related to revenue and EBITDA growth rates, discount rates, and attrition factors. Inputs are generally determined by taking into account competitive trends, market comparisons, independent appraisals, and historical data, among other factors, and were supplemented by current and anticipated market conditions. Variances in future cash flows, anticipated growth rates, and revenue could significantly impact the value assigned to intangible assets. Any variance could cause impairment charges upon testing.

Impairment Testing

We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change indicating the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic industry and market factors; cost factors; changes in overall financial performance; and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we perform a test measuring the fair values of the reporting units and comparing them to their aggregate carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill.

Discount rates will be determined for each reporting unit and include consideration of the implied risk inherent in their forecasts. Our most significant estimate in the discount rate determinations involves our adjustments to the peer company weighted average costs of capital reflecting reporting unit-specific factors. We do not make any adjustments to decrease a discount rate below the calculated peer company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty.

During the nine months ended September 30, 2024, the Company determined that triggering events occurred, which required interim testing for impairment in accordance with ASC 350. We elected to perform a quantitative analysis as part of our interim goodwill impairment test. Our analysis of the PulseVet reporting unit indicated that its fair value exceeded its carrying amount, including goodwill, by 56%. Our analysis of the Revo Squared, SMP and Assisi reporting units indicated that their respective fair values were below their carrying amounts, including goodwill, by 64%, 80% and 3%, respectively. This was driven by slowed future sales growth projections and the allocation of operating expenses. As a result, a goodwill impairment charge of $16,024 was recorded for the three and nine months ended September 30, 2024, as part of the Company’s interim goodwill impairment test.

Table of Contents

The carrying values of goodwill for the PulseVet and Assisi reporting units at September 30, 2024, were $43.4 million and $2.2 million, respectively. Following the impairment recorded in the current period, there are no longer carrying values of goodwill for the Revo Squared or SMP reporting units.

The implied fair value for each reporting unit was calculated on a standalone basis using a weighted combination of the income approach and market approach. The implied fair values of each reporting unit were added together along with our unallocated assets to get an indicated value of total equity. This indicated value was compared to the total market capitalization as of September 30, 2024. This implied a control premium of 59.3%. This control premium is in line with the control premiums observed in the last five years in the Medical, Dental, and Hospital Equipment and Supplies industry, which have historically been significantly higher than the aggregate control premiums across all other industries. As a result, the market capitalization reconciliation analysis provided support for the reasonableness of the fair values estimated for each individual reporting unit.

While the Company continues to believe its estimates of fair value are reasonable, changes in assumptions concerning future financial results, an increase in the discount rate, or other underlying assumptions could significantly impact the fair value of the reporting units. The Company could be required to record an impairment charge in future periods. Additionally, future declines in the overall market value of the Company’s equity may result in a conclusion that the fair value of one or more reporting units has declined below its carrying value.

Valuation and Payback of Property and Equipment

Diagnostic based TRUFORMA^® capital is placed in fixed assets once purchased or manufactured, where they remain, undepreciated, until they are placed with our customers under the agreement that they will repeatedly purchase consumables or services which are utilized within. Each instance of this placed capital represents an asset that we own. An estimate is made of the anticipated future revenue over its respective life which is ten years. If the payback period of the initial investment in the asset is less than the ten-year life of the asset, we conclude that the assets have been properly recorded, and no write-down is necessary. We rely on various data points and assumptions, including, but not limited to, the expected volume of consumables which will be sold, anticipated growth rates, and anticipated placements. Realization of the anticipated revenue is dependent on the current assumptions and forecasted models.

The customer is obligated to purchase consumables during the placement period. However, since the customer is not obligated to purchase the capital, and can return it at any time, we are exposed to a risk of loss to the extent the customer returns the capital and discontinues consumable or related service purchases.

As of September 30, 2024, the carrying value of our Diagnostic instruments was $10,268. Significant assumptions included in the realization model are the rate of placement and expected utilization over the life of the instrument. A 25% reduction in the estimated revenues associated with annual placements of instruments would increase the payback period from 2.66 years to 3.53 years as of September 30, 2024.

Revenue Recognition and Liabilities Due to Customers

The nature of our Therapeutic Device business segment gives rise to variable consideration, including discounts and applicator (“trode”) returns for refurbishment. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. When revenue is recognized, a simultaneous adjustment for returns is estimated, reducing revenue. Estimated return credits are presented as a reduction to gross sales with the corresponding reserve presented as customer contract liabilities.

Variable consideration related to unused shock credits is calculated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are non-refundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, enabling the customer to always have a trode on hand with ample capacity to perform treatments.

The number of trodes returned by year is tracked against the number of trodes sold in that same year, creating a current experience rate. It is assumed that the ultimate return rate for the trodes is 98%. For annual calculations, it is assumed that the expected returns in the current year for each layer increase to the experience rate of the year immediately preceding it. Once the 98% is reached the layer is removed from the calculation. The annual incremental change in expected returns is multiplied by an average return credit amount, generating the current liability due to customers.

Table of Contents

The average return credit is calculated by dividing the actual shock credits issued by the actual number of trodes returned. A variance in the assumed return rate compared to the actual rate would impact the estimate and potentially understate net sales (overestimated rate) or overstate net sales (underestimated rate) in any given year and create a corresponding misstatement of the liability due to customers.

As of September 30, 2024, the estimated value of our Therapeutic Device customer contract liability was $553. If the expected return rate had increased by 2%, the effect on current year’s reduction in sales and customer liability would have been approximately $90.

Results of Consolidated Operations

Our results of operations for the three and nine months ended September 30, 2024 and 2023 are as follows:

Revenue

Revenue for the three months ended September 30, 2024 was $6,997, compared to $6,347 for the three months ended September 30, 2023, an increase of $650, or 10%. Revenue for the nine months ended September 30, 2024 was $19,390, compared to $17,849 for the nine months ended September 30, 2023, an increase of $1,541, or 9%.

The increase in sales for the three months ended September 30, 2024, was primarily due to growth in both consumables and capital sales in our existing PulseVet^® products, as well as growth in TRUFORMA^® products, including the impact of launching new assays during the comparative period. The increase in sales for the nine months ended September 30, 2024, was primarily due to growth in both consumables and capital sales in our PulseVet^® products, as well as growth in TRUFORMA^® products, partially attributable to the launch of new assays during the comparative period, and the continued performance of VetGuardian^®, which had only recently launched during the nine months ended September 30, 2023. In general, we expect revenue to increase in subsequent periods as we increase our sales, marketing, and commercialization efforts.

Cost of Revenue

Cost of revenue for the three months ended September 30, 2024 was $1,937, compared to $1,985 for the three months ended September 30, 2023, a decrease of $48, or 2%. Cost of revenue for the nine months ended September 30, 2024 was $5,851, compared to $5,604 for the nine months ended September 30, 2023, an increase of $247, or 4%.

The decrease in cost of revenue for the three months ended September 30, 2024, was primarily due to lower costs realized from the further integration of our Minnesota manufacturing facility, acquired in the second half of 2023, partially offset by increased manufacturing expenses driven by higher unit sales. The increase in cost of revenue for the nine months ended September 30, 2024, was primarily driven by increased manufacturing expenses resulting from higher unit sales. We anticipate that cost of revenue will continue to increase in future periods in line with the expected growth in unit sales, as described above.

Gross Profit

Gross profit margin for the three months ended September 30, 2024 was 72%, compared to 69% for the three months ended September 30, 2023. Gross profit margin for the nine months ended September 30, 2024 was 70%, compared to 69% for the nine months ended September 30, 2023.

The increase in gross profit margin percentage for both the three and nine months ended September 30, 2024, was primarily due to improvements associated with the integration of our Minnesota manufacturing facility, as well as the further absorption of fixed costs driven by increased unit sales.

General and Administrative

General and administrative expense for the three months ended September 30, 2024 was $6,765, compared to $6,115 for the three months ended September 30, 2023, an increase of $650, or 11%. General and administrative expense for the nine months ended September 30, 2024 was $23,366, compared to $19,977 for the nine months ended September 30, 2023, an increase of $3,389, or 17%.

The increase in general and administrative expenses for the three months ended September 30, 2024, was primarily driven by professional fees for specialized accounting and development work, higher than usual adjustments to the Revo Squared earnout liability in the prior comparative period, and increased amortization expense associated with acquisitions made in the second half of 2023. These increases were partially offset by lower stock-based compensation expense, including the impact of forfeitures related to the departure of our former Chief Financial Officer during the current period. The increase in general and administrative expenses for the nine months

Table of Contents

ended September 30, 2024, was primarily driven by professional fees for specialized accounting and development work, increased amortization expense associated with acquisitions made in the second half of 2023, proxy and special meeting costs, and higher than usual adjustments to the Revo Squared earnout liability in the prior comparative period. These increases were partially offset by lower stock-based compensation expense. While we expect future general and administrative expenses to increase, we anticipate they will decrease proportionally relative to sales and related product expansion.

Research and Development

Research and development expense for the three months ended September 30, 2024 was $1,845, compared to $867 for the three months ended September 30, 2023, an increase of $978, or 113%. Research and development expense for the nine months ended September 30, 2024 was $5,122, compared to $2,645 for the nine months ended September 30, 2023, an increase of $2,477, or 94%.

The increase in research and development expenses for both comparative periods was driven primarily by the continued buildup of internal capabilities to develop, test, and manufacture our next generation of diagnostic products. We anticipate that R&D costs will increase as we maintain and enhance our current product lines and continue to develop new products.

Selling and Marketing

Selling and marketing expense for the three months ended September 30, 2024 was $3,890, compared to $3,328 for the three months ended September 30, 2023, an increase of $562, or 17%. Selling and marketing expense for the nine months ended September 30, 2024 was $11,920, compared to $9,826 for the nine months ended September 30, 2023, an increase of $2,094, or 21%.

The increase in selling and marketing expenses for both comparative periods was driven primarily by salaries and commissions, associated with increased hiring campaigns and increased marketing campaigns / attendance at tradeshows to build brand awareness and recognition of our expanding suite of products. We expect future selling and marketing expense to increase in line with product expansion and growth in our commercialization efforts.

Impairment Expense

No impairment expense was recognized for either the three months ended September 30, 2024, or the three months ended September 30, 2023. For the nine months ended September 30, 2024, impairment expense was $16,024, compared to $0 for the nine months ended September 30, 2023. The increase was due to the goodwill impairment recognized earlier in the year, driven by slowed future sales growth projections and the allocation of operating expenses.

Other (Loss) Income

Other expense for the three months ended September 30, 2024 was $111, compared to Other income of $2,195 for the three months ended September 30, 2023, a net change of $2,306. Other income for the nine months ended September 30, 2024 was $25, compared to $2,195 for the nine months ended September 30, 2023, a decrease of $2,170, or 99%. The change in both comparative periods was primarily due to a gain of $2,174 on the fair valuation of the Company’s previously held equity interest in SMP, which was recognized during the three and nine months ended September 30, 2023.

Net Loss

Net loss for the three months ended September 30, 2024 was $6,697 compared to a net loss of $491 for the three months ended September 30, 2023, an increase of $6,206, or 1264%. Net loss for the nine months ended September 30, 2024 was $39,788, compared to a net loss of $12,123 for the nine months ended September 30, 2023, an increase of $27,665, or 228%.

The net loss for each comparative period was attributed to the matters described above, as well as to tax-related benefits recognized during the three and nine months ended September 30, 2023, which were attained as part of the SMP acquisition. We expect to continue recording net losses in future periods until we have sufficient revenue from product sales to offset our operating expenses.

Table of Contents

Cash Flows

The following table shows a summary of our cash flows for the periods set forth below:


	Nine Months Ended September 30,
	2024		2023		Change
Cash used in operating activities	$	(19,105)	$	(10,960)	$	(8,145)	74%
Cash provided by investing activities		15,938		5,406		10,532	195%
Cash used in financing activities		(70)		—		(70)	n/a
Decrease in cash and cash equivalents		(3,237)		(5,554)		2,317	(42)%
Effect of exchange rate changes on cash		32		(62)		94	(152)%
Cash and cash equivalents, beginning of period		12,952		27,399		(14,447)	(53)%
Cash and cash equivalents, end of period	$	9,747	$	21,783	$	(12,036)	(55)%

Net cash used in operating activities for the nine months ended September 30, 2024 was $19,105, compared to $10,960 for the nine months ended September 30, 2023, an increase in cash used of $8,145, or 74%. The increase in cash used in operating activities resulted primarily from the increase in net loss noted above, excluding the impact of non-cash charges, including stock-based compensation, impairment expense, and amortization of intangible assets.

Net cash provided by investing activities for the nine months ended September 30, 2024 was $15,938, compared to $5,406 for the nine months ended September 30, 2023, an increase in cash provided of $10,532, or 195%. The increase in cash provided by investing activities resulted primarily from cash paid as a part of the SMP acquisition during the prior period, which did not recur and decreased capital expenditures for the nine months ended September 30, 2024, partially offset by lower maturity of available-for-sale securities.

Net cash used in financing activities for the nine months ended September 30, 2024, was $70, compared to $0 for the nine months ended September 30, 2023, an increase of $70. The increase was attributable to stock option issuance costs paid during the third quarter of 2024.

Liquidity, Capital Resources, and Financial Condition

We have incurred losses and negative cash flows from operations since our inception in May 2015. As of September 30, 2024, we had an accumulated deficit of $210,721. We have funded our working capital requirements primarily through the sale of our equity and equity-related securities and the exercise of stock options and warrants.

As of September 30, 2024, the Company had working capital (defined as current assets minus current liabilities) of $79,206.

Short-Term Cash Requirements

We believe that our existing cash is sufficient to fund our expected short-term needs. We currently have fixed obligations in association with our building leases and quarterly inventory orders. We also have payment obligations associated with our on-going clinical studies, and we believe that we have sufficient cash to cover these requirements. We do not expect that our operations will require significant increases in our short-term cash needs, and our short-term cash requirements have not changed materially since the 2023 Form 10-K.

Long-Term Cash Requirements

We believe that our existing cash resources will be sufficient to fund our expected operational requirements for the foreseeable future. We regularly evaluate our business plans and strategy. These evaluations often result in changes to our business plans and strategy, some of which may be material and significantly change our cash requirements. Ongoing business development activity may also require us to use some of our liquidity and use of additional capital to fund newly acquired operations. If we raise additional funds by issuing equity securities, our existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that could restrict operations.

Our future capital requirements depend on many factors, including, but not limited to:

●

the costs and timing of our development and commercialization activities;

●

the cost of manufacturing our existing and future products;

Table of Contents

●

the cost of marketing and selling our existing and future products including marketing, sales, service, customer support and distribution costs;

●

the expenses needed to attract and retain skilled personnel;

●

the costs associated with being a public company;

●

the costs associated with additional business development or mergers and acquisitions activity, including acquisition-related costs, earn-outs or other contingent payments and costs of developing and commercializing any technologies to which we obtain rights;

●

third-party costs associated with the development and commercialization of our existing and future products and the ability of our development partners to satisfy our requirements on a timely basis;

●

the scope and terms of our business plans from time to time, and our ability to realize upon our business plans; and

●

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

The Company’s long-term cash requirements have not changed materially since the 2023 Form 10-K.

U.S. Taxes

As of September 30, 2024, we had deferred tax assets for net operating loss carryforwards for U.S. federal income tax purposes of $15,214 and non-capital loss carryforwards for Canada of $9,581, which will begin to expire in fiscal year 2035. We have evaluated the factors bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and non-capital loss carryforwards. In 2021, we concluded that, due to the limitations under Section 382, our U.S. federal income tax net operating loss carryforwards, as well as R&D credit carryforwards, for the periods prior to February 11, 2021 have been limited to zero. We therefore have derecognized $3,814 of this asset, reducing the carryforward of these amounts to $11,400.

Climate Change

Increased public awareness and concern about climate change will likely continue to (1) generate more regional and/or national requirements to reduce greenhouse gas emissions; (2) increase energy efficiency and reduce carbon pollution; and (3) cause a shift to cleaner and more sustainable sources of energy which may be more expensive than using fossil fuels as an energy source.

The potential impact of climate change on our operations and the needs of our customers remains uncertain. Scientists have proposed that the impacts of climate change could include changes in rainfall patterns, water shortages, changes to the water levels of lakes and other bodies of water, changing storm patterns, more intense storms and changing temperature levels. These changes could be severe and vary by geographic location. Climate change may also affect the occurrence of certain natural events, the incidence and severity of which are inherently unpredictable.

The effects of climate change also may impact our decisions to construct new buildings or maintain existing facilities in any areas that are or become prone to physical risks, which could similarly increase our operating costs. We could also face indirect financial risks passed through the supply chain that could result in higher prices for resources, such as energy. Additionally, climate change may adversely impact the demand, price and availability of property and casualty insurance that insures our physical assets. Due to significant economic variability associated with future changing climate conditions, we are unable to predict the impact climate change will have on us in the future.

Other Matters: Adoption of Stock Appreciation Rights Plan

On August 12, 2024, the Board of Directors of Zomedica Corp. (the “Company”) adopted the Zomedica Corp. 2024 Stock Appreciation Rights Plan (the “SAR Plan”). The SAR Plan will be administered by the Board of Directors of the Company (the “Board”); the Board may delegate administration of the SAR Plan to a committee of the Board. Up to 10% of the issued and outstanding shares of common stock of the Company (calculated on a non-diluted basis) is available for the grant of stock appreciation rights (“SARs”) under the SAR Plan, subject to adjustment as provided in the SAR Plan. This is a limit on the number of SARs that can be issued under the SAR Plan; however, no shares are issued under the SAR Plan upon the exercise of a SAR and awards are settled solely in cash.

Table of Contents

The Board may make SAR awards to employees, consultants and directors of the Company or any affiliate of the Company, including Zomedica Inc. The exercise price of a SAR will be determined by the Board, but will not be less than the fair market value of one share of common stock on the grant date. The Board will also determine the term of the SAR, which may not exceed ten years, and establish the vesting provisions of each SAR. Upon exercise of a SAR, the participant will receive a cash payment equal to the excess of the fair market value of a share of common stock on the exercise date over the exercise price of the SAR.

Following termination of a participant’s service with the Company, the participant may exercise any vested SARs within 90 days or the expiration date of the SAR, if earlier. The exercise period is extended to 12 months if the separation from service is due to death or disability of the participant, or the expiration date of the SAR, if earlier.

The Board also adopted a form of stock appreciation rights agreement for employees, and a form of stock appreciation rights agreement for directors.

The foregoing description of the SAR Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the SAR Plan, the form of stock appreciation rights agreement for employees and the form of stock appreciation rights agreement for directors, copies of which are filed as Exhibit 10.3 and 10.4, respectively, to this Quarterly Report on Form 10-Q and incorporated herein by reference.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Evaluation of our disclosure controls

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized, and reported within the specified time periods and accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer.

Based upon the evaluation as of December 31, 2023, our principal executive officer and principal financial and accounting officer concluded that, our disclosure controls and procedures were not effective because of the material weakness in internal control over financial reporting described below and in Part II, Item 9A, "Controls and Procedures" of our 2023 Form 10-K. The material weakness has been remediated as of September 30, 2024.

Management's report on internal control over financial reporting

Our management is responsible for establishing and maintaining effective internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. This system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with GAAP. Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, misstatements due to error or fraud may not be prevented or detected on a timely basis.

Our management including our principal executive officer and principal financial and accounting officer, performed an assessment of the effectiveness of our internal control over financial reporting as of September 30, 2024, utilizing the criteria discussed in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The objective of this assessment was to determine whether our internal control over financial reporting was effective as of September 30, 2024. Based on management's assessment, we have concluded that our internal control over financial reporting was effective as of September 30, 2024, due to the remediation of the material weakness described below.

Prior Year Material Weaknesses

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a

reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As disclosed in Part II, Item 9A, "Controls and Procedures" of our 2023 Form 10-K, we identified the following weakness in internal controls:

Table of Contents

As of December 31, 2023, there was a material weakness relating to the timeliness and precision of management's review controls around financial projections relevant to the evaluation of goodwill impairment relating to our Assisi product line.

Remediation status for material weakness in internal control over financial reporting

During the second quarter of 2024, we implemented our remediation plan around the previously disclosed material weakness in relation to our annual impairment test of goodwill.

The Company completed a cross-functional review of year-to-date results and revised them as appropriate, including revising our estimates on the allocation of operating expenses not directly attributable to a specific reporting unit. To achieve the revised estimates, the Company and third-party consultants developed modeling that enabled transparent allocations of expenses to each reporting unit. All inputs and assumptions into the valuation model were reviewed with the appropriate responsible Company personnel. The Company ensured that the outputs of the valuation model are consistent and reasonable with known business conditions. The results of the analysis and impacts were appropriately and timely reviewed, ensuring consensus on the accounting conclusions. Based on the actions taken, as well as the evaluation of the design of the control, management concluded that the material weakness was remediated as of June 30, 2024.

For the three months ended September 30, 2024, management continued to monitor the effectiveness of the revised internal controls and confirmed that no further issues or material weaknesses have arisen. Based on this ongoing assessment, management concluded that our disclosure controls and procedures over financial reporting were effective as of September 30, 2024.

Changes in Internal Control Over Financial Reporting

Other than as discussed above, during the three months ended September 30, 2024 there were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.

Table of Contents

Item 6. Exhibits.

The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.

EXHIBIT INDEX

Exhibit No.		Description

10.1+		Consulting Agreement, dated August 14, 2024, between Zomedica Inc. and Peter Donato (incorporated by reference to Exhibit 10.1 to the Company's Form 8-K filed with the Commission on August 14, 2024).
10.2+		Separation Agreement, dated August 14, 2024, between Zomedica Inc. and Peter Donato (incorporated by reference to Exhibit 10.2 to the Company's Form 8-K filed with the Commission on August 14, 2024).
10.3+		Stock Appreciation Rights Agreement (Employees)
10.4+		Stock Appreciation Rights Agreement (Directors)
10.5+		Stock Appreciation Rights Plan
31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Vice President of Finance and Corporate Controller, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Chief Executive Officer and Vice President of Finance and Corporate Controller, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.
101.INS		Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL (1).
101.SCH		Inline XBRL Taxonomy Extension Schema Document (1).
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document (1).
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document (1).
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document (1).
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document (1).
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.1)

+	Indicates management contract or compensatory plan.

*	Furnished herewith

**	Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 7, 2024.


	Zomedica Corp.

	By:	/s/ Larry Heaton
	Name:	Larry Heaton
	Title:	Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Michael Zuehlke
	Name:	Michael Zuehlke
	Title:	Vice President of Finance and Corporate Controller
		(Principal Financial and Accounting Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

Zomedica (ZOM) 10-Q2024 Q3 Quarterly report

Content analysis